Who is sponsoring NCT03712644?

NCT03712644 is sponsored by Medical University of Graz.

What drugs are being tested in NCT03712644?

Interventions in NCT03712644: FFR-guided coronary revascularization.

What condition does NCT03712644 study?

NCT03712644 studies Obstructive Coronary Artery Disease.

Is NCT03712644 still recruiting?

NCT03712644 is currently status unknown. Last updated 6 November 2018.

Last reviewed 2018-11-06 · How we verify

NCT03712644: INCORPORATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Coronary Revascularization Versus Conservative Therapy in Patients With Treated Critical Limb Ischemia

Status unknown NA Last updated 6 November 2018

What this trial tests

NA trial testing FFR-guided coronary revascularization in Obstructive Coronary Artery Disease in 650 participants. Status unknown.

Timeline

11 July 2018

Primary endpoint
31 August 2021

31 August 2022

Quick facts

Lead sponsor	Medical University of Graz
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	650
Start date	11 July 2018
Primary completion	31 August 2021
Estimated completion	31 August 2022
Sites	2 locations across Austria, Hungary

Drugs / interventions tested

FFR-guided coronary revascularization

Conditions studied

Obstructive Coronary Artery Disease — all drugs for Obstructive Coronary Artery Disease →

Sponsor

Medical University of Graz

Who can join

Adults 18 to 100, any sex, with Obstructive Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the INCORPORATE trial is to evaluate whether an intentional invasive strategy with ischemia targeted, reasonably complete coronary revascularization and optimal medical therapy is superior as compared to a primary conservative approach and optimal medical therapy alone in terms of spontaneous myocardial infarct-free and overall survival in patients with severe peripheral artery disease, underwent peripheral artery revascularization due to critical limb ischemia. The INCORPORATE trial is designed to be non-blinded, open-label, prospective 1:1 randomized controlled multicentric trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial).
Toth G, Brodmann M, Barbato E, Mangiacapra F, et al · · 2019 · cited 3× · PMID 31200280 · DOI 10.1016/j.ahj.2019.05.005
Intentional coronary revascularization versus conservative therapy in patients after peripheral artery revascularization due to critical limb ischemia: the INCORPORATE trial.
Toth GG, Brodmann M, Kanoun Schnur SS, Bartus S, et al · · 2025 · cited 1× · PMID 38990250 · DOI 10.1007/s00392-024-02487-2

Verify or expand the search:

Other recruiting trials for Obstructive Coronary Artery Disease

Currently open trials in the same condition.

NCT07116083 — µQFR for Branch Stenosis After Single Stent in Bifurcation Lesions · recruiting

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03712644 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 6 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03712644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing